Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report

Guoliang Pi, Hanping He, Jianping Bi, Ying Li, Yanping Li, Yong Zhang, Mingwei Wang, Guang Han, Chi Lin

Research output: Contribution to journalArticle

Abstract

Introduction: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown. CaseReport: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1. Conclusion: To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.

Original languageEnglish (US)
Article numbere5077
JournalMedicine (United States)
Volume95
Issue number40
DOIs
StatePublished - Jan 1 2016

Fingerprint

Squamous Cell Carcinoma
Lung
Therapeutics
nivolumab
Immunotherapy
Immunoglobulin G
Clinical Trials
Ligands
Drug Therapy
Survival
Antibodies
Neoplasms

Keywords

  • Lung squamous cell carcinoma
  • Nivolumab
  • PD-L1
  • Relapsed
  • Short-term

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma : A case report. / Pi, Guoliang; He, Hanping; Bi, Jianping; Li, Ying; Li, Yanping; Zhang, Yong; Wang, Mingwei; Han, Guang; Lin, Chi.

In: Medicine (United States), Vol. 95, No. 40, e5077, 01.01.2016.

Research output: Contribution to journalArticle

Pi, Guoliang ; He, Hanping ; Bi, Jianping ; Li, Ying ; Li, Yanping ; Zhang, Yong ; Wang, Mingwei ; Han, Guang ; Lin, Chi. / Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma : A case report. In: Medicine (United States). 2016 ; Vol. 95, No. 40.
@article{d8e9a851921f4c868efb049d9974ae6b,
title = "Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report",
abstract = "Introduction: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown. CaseReport: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1. Conclusion: To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.",
keywords = "Lung squamous cell carcinoma, Nivolumab, PD-L1, Relapsed, Short-term",
author = "Guoliang Pi and Hanping He and Jianping Bi and Ying Li and Yanping Li and Yong Zhang and Mingwei Wang and Guang Han and Chi Lin",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000005077",
language = "English (US)",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "40",

}

TY - JOUR

T1 - Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma

T2 - A case report

AU - Pi, Guoliang

AU - He, Hanping

AU - Bi, Jianping

AU - Li, Ying

AU - Li, Yanping

AU - Zhang, Yong

AU - Wang, Mingwei

AU - Han, Guang

AU - Lin, Chi

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown. CaseReport: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1. Conclusion: To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.

AB - Introduction: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown. CaseReport: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1. Conclusion: To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.

KW - Lung squamous cell carcinoma

KW - Nivolumab

KW - PD-L1

KW - Relapsed

KW - Short-term

UR - http://www.scopus.com/inward/record.url?scp=84995596022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995596022&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000005077

DO - 10.1097/MD.0000000000005077

M3 - Article

C2 - 27749580

AN - SCOPUS:84995596022

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 40

M1 - e5077

ER -